Chemistry:Pexelizumab
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | Complement component 5 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
Current status
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]
References
- ↑ Clinical trial number NCT00088179 for "Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00091637 for "Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction" at ClinicalTrials.gov
- ↑ "Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients". The Journal of Thoracic and Cardiovascular Surgery 136 (4): 884–93. October 2008. doi:10.1016/j.jtcvs.2007.12.062. PMID 18954626.
- ↑ "Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery". Stroke 35 (10): 2335–9. October 2004. doi:10.1161/01.STR.0000141938.00524.83. PMID 15331798.
- ↑ Mitchell, Steve (2 January 2007). "Analysis: Alexion's pexelizumab fails". United Press International. http://www.upi.com/Health_News/2007/01/02/Analysis-Alexions-pexelizumab-fails/UPI-61131167778114.
 |  |
